[The retrospective analysis of different therapies on 150 elderly patients with advanced non-small cell lung cancer.].

@article{Zheng2009TheRA,
  title={[The retrospective analysis of different therapies on 150 elderly patients with advanced non-small cell lung cancer.].},
  author={Ji-Hua Zheng and Wei-min Zhang and Hai Chen and Zhiyong Xu and Juan Zhou and Bo Xie and Lixia Li and Jin-rong Lin},
  journal={Zhongguo fei ai za zhi = Chinese journal of lung cancer},
  year={2009},
  volume={12 2},
  pages={
          122-6
        }
}
BACKGROUND There is still no standard regiment for the treatment of advanced elderly patients with non-small cell lung cancer (NSCLC). The aim of this study is to explore the best method for the advanced elderly NSCLC patients by analyzing the efficacy and toxicity of cisplatin combined chemotherapy, docetaxel chemotherapy and the best support care (BSC). METHODS One hundred and fifty elderly NSCLC patients (>=65 years) with different treatments from March 2003 to March 2007 in our hospital… 
1 Citations

Figures from this paper

[The status and prospects of treatment protocols for elderly patients with non-small cell lung cancer].
TLDR
The current status and prospect of treatment protocols for elderly patients with non-small cell lung cancer and the general acceptance of treatment more than best supportive care in the elderly patients is not optimistic.

References

SHOWING 1-8 OF 8 REFERENCES
Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial.
TLDR
Although quality of life was similar across the three treatment arms, the combination treatment was more toxic than the two drugs given singly and not more effective than single-agent vinorelbine or gemcitabine in the treatment of elderly patients with advanced NSCLC.
Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial.
TLDR
Responsibility rate, toxicity, and survival in fit, elderly NSCLC patients receiving platinum-based treatment appear to be similar to those in younger patients, although patients 70 years old or older have more comorbidities and can expect more leukopenia and neuropsychiatric toxicity.
Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis.
TLDR
Chemotherapy for stage IV NSCLC seems to have effectiveness for elderly patients and those with comorbid conditions that is similar to the efficacy seen in randomized trials containing mostly younger, highly selected patients.
Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).
TLDR
Combination chemotherapy improves response rate and failure-free survival compared with single-agent therapy, but there was no statistically significant difference in the primary end point of overall survival.
Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group.
TLDR
Vinorelbine improves survival of elderly patients with advanced NSCLC and possibly improves overall quality of life (QoL) in a multicenter randomized trial that compared vinore lbine treatment with supportive care alone.
The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel
TLDR
A retrospective analysis of a Phase III trial that treated patients who had Stage IIIB or IV nonsmall cell lung carcinoma with carboplatin and paclitaxel and analyzed the impact of age on response rate, survival, toxicity, and quality of life.
Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma
Weekly administration of docetaxel was found to reduce myelosuppression and other nonhematologic toxicities when compared with administration every 3 weeks. In the current Phase II trial, the authors
Lung cancer in the elderly patient.
One half of all cases of lung cancer occur in patients aged 65 years and older. Although adenocarcinoma is the predominant histologic subtype in the general population, squamous cell carcinoma has